BTCY — Biotricity Income Statement
0.000.00%
Last trade - 00:00- $12.46m
- $38.49m
- $12.06m
- 50
- 58
- 64
- 58
Annual income statement for Biotricity, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
R2020 March 31st | C2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1.42 | 3.38 | 7.65 | 9.64 | 12.1 |
| Cost of Revenue | |||||
| Gross Profit | 0.486 | 1.27 | 4.57 | 5.44 | 8.36 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 12.3 | 16.8 | 26.8 | 25.1 | 20.9 |
| Operating Profit | -10.9 | -13.5 | -19.2 | -15.5 | -8.81 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -11.1 | -15.5 | -29.1 | -18.7 | -14.1 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -11.1 | -15.5 | -29.1 | -18.7 | -14.1 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -11.1 | -15.5 | -29.1 | -18.7 | -14.1 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -11.3 | -16.5 | -30.2 | -19.5 | -14.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.89 | -2.61 | -3.84 | -2.25 | -1.66 |